Taiwan Stock Exchange · Healthcare
YungShin Global stock from India: price, numbers and tax
YungShin Global (3705) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
YungShin Global at a glance
- Price
- NT$56.20-NT$0.50 (0.88%)
- Market cap
- NT$14.97B
- Day range
- NT$56.20 – NT$56.70
- P/E
- 16.78
- Dividend yield
- 5.34%
- Volume
- 6.59K
- 1 month
- +0.72%
- 6 months
- +3.88%
- YTD
- -1.40%
- 1 year
- -4.10%
- 5 years
- +31.46%
YungShin Global statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$8.4B | NT$8.0B | NT$7.0B | NT$7.3B | NT$7.8B |
| Gross profit | NT$3.6B | NT$3.5B | NT$3.0B | NT$3.1B | NT$3.7B |
| Operating income | NT$1.3B | NT$1.3B | NT$929.6M | NT$757.9M | NT$960.6M |
| Net income | NT$880.8M | NT$1.2B | NT$827.3M | NT$839.0M | NT$736.6M |
| Earnings per share | NT$3.30 | NT$4.39 | NT$3.11 | NT$3.15 | NT$2.77 |
| EBITDA | NT$1.6B | NT$1.9B | NT$1.5B | NT$1.5B | NT$1.4B |
| Total assets | NT$12.6B | NT$13.8B | NT$11.5B | NT$11.9B | NT$12.0B |
| Total debt | NT$1.2B | NT$1.2B | NT$1.2B | NT$1.8B | NT$2.7B |
| Cash and short-term investments | NT$2.5B | NT$2.3B | NT$1.8B | NT$2.0B | NT$1.3B |
| Shareholders' equity | NT$8.2B | NT$8.0B | NT$7.3B | NT$7.2B | NT$6.5B |
| Operating cash flow | NT$1.5B | NT$1.4B | NT$1.2B | NT$967.2M | NT$968.4M |
| Free cash flow | NT$1.0B | NT$1.1B | NT$1.1B | NT$796.5M | NT$787.6M |
| Capital expenditure | −NT$508.4M | −NT$226.6M | −NT$87.6M | −NT$170.7M | −NT$180.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Handa Pharmaceuticals | 6620.TWO | $147.00 | $24.48B |
| TTY Biopharm | 4105.TWO | $78.40 | $19.49B |
| Synmosa Biopharma | 4114.TWO | $29.45 | $15.89B |
| ScinoPharm Taiwan | 1789.TW | NT$18.85 | NT$14.91B |
| Excelsior Medical | 4104.TW | NT$72.40 | NT$13.64B |
| Grape King Bio | 1707.TW | NT$85.40 | NT$12.65B |
| Foresee Pharmaceuticals | 6576.TWO | $79.20 | $12.48B |
| Standard Chem & Pharm | 1720.TW | NT$55.90 | NT$10.99B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in YungShin Global from India
What YungShin Global does
YungShin Global Holding Corporation, through its various subsidiaries, engages in strategic investments, production, and distribution across a diverse portfolio. Its primary focus lies in the manufacturing and sale of human and veterinary pharmaceuticals, agricultural chemicals, industrial medical products, and cosmetics. YungShin Global operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell YungShin Global shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.